Drug Trial Radar · NCT05535764
AlloHCT With PegINFa for Myelofibrosis
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Aug 2, 2023
Primary completion
Jan 2027
Study completion Mar 2028
Sponsor
- Lead sponsor
- University of UtahAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Huntsman Cancer Institute
- First posted
- Sep 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single site, open-label, dose de-escalation, Phase 1 study of pegylated interferon alfa-2a administered after alloHCT in subjects with primary or secondary myelofibrosis. Part 1 of the study will assess the rate of dose-limiting toxicities (DLTs) during the DLT evaluation period and identify the Recommended Phase 2 Dose (RP2D). Once the RP2D is identified, 6 additional patients will be enrolled in the expansion cohort.
Conditions
- Myelofibrosis
Interventions
Pegylated interferon alpha2aDrug
PegINFa will be given once every 2 weeks by subcutaneous administration in the abdomen or thigh.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of dose-limiting toxicities (DLTs) during the DLT evaluation periodTime frame: Start of treatment to 86 days after treatment initiation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.